Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 11/20 | 0.40 |
| ▸ | SMO | Q99835 | 9/20 | 0.40 |
| ▸ | APOB | P04114 | 8/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.40 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.40 |
| ▸ | ITGAV | P06756 | 2/20 | 0.40 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6492134 | 0.92 | MTTP (0.50) | MTTPSMOAPOB | |
| SCHEMBL6787323 | 0.89 | POLB (0.42) | ITGB3ITGB1ITGAVITGA5CHRNB2 | |
| SCHEMBL6489654 | 0.87 | APOB (0.40) | MTTPAPOBITGB3ITGB1ITGAV | |
| SCHEMBL6490619 | 0.87 | ITGB3 (0.39) | ITGB3ITGB1ITGAVITGA5CHRNB2 | |
| SCHEMBL6499215 | 0.84 | ITGB1 (0.43) | MTTPSMOAPOBITGB1ITGA5 | |
| SCHEMBL6646068 | 0.81 | ITGB3 (0.41) | ITGB3ITGB1ITGAVITGA5CHRNB2 | |
| SCHEMBL6492604 | 0.81 | MTTP (0.42) | MTTPSMOAPOBITGB3ITGB1 | |
| SCHEMBL6491507 | 0.81 | MTTP (0.49) | MTTPSMOAPOBCHRNB2CHRNB4 | |
| SCHEMBL6650060 | 0.81 | ITGB3 (0.40) | ITGB3ITGB1ITGAVITGA5CHRNB2 | |
| SCHEMBL6789234 | 0.81 | SMO (0.47) | MTTPSMOAPOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | MTTP 677/4885SMO 2580/4885APOB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.